Stifel Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)

July 10, 2025 7:24 AM EDT Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $95.00 price target on Apogee Therapeutics Inc (NASDAQ: APGE).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login